No­var­tis' ap­proved sick­le cell dis­ease drug fails to beat place­bo in PhI­II

No­var­tis’ sick­le cell drug, ap­proved in 2019 and brand­ed as Adakveo, has failed an on­go­ing Phase III, ac­cord­ing to pre­lim­i­nary re­sults.

The Swiss phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER